Cellular Biomedicine Group, Inc. (CBMG) Financial Statements (2024 and earlier)

Company Profile

Business Address 209 PERRY PARKWAY
GAITHERSBURG, MD 20877
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2020
MRQ
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 15,44452,81321,56839,25214,88514,771
Cash and cash equivalents 15,44452,81321,56839,25214,88514,771
Restricted cash and investments 17,000     
Receivables  120340780141
Inventory, net of allowances, customer advances and progress billings     391372
Inventory     391372
Intangible current assets      11,157
Other current assets      110
Other undisclosed current assets 1,5861,7942,7561,400638(10,455)
Total current assets: 34,03054,60824,52740,69216,69416,095
Noncurrent Assets
Operating lease, right-of-use asset 20,106
Property, plant and equipment 21,43415,19412,9734,1182,7691,280
Long-term investments and receivables 2402402695095,3796,886
Long-term investments 2402402695095,3796,886
Intangible assets, net (including goodwill) 7,6797,6797,6797,6797,67918,835
Goodwill 7,6797,6797,6797,6797,6797,679
Intangible assets, net (excluding goodwill)      11,157
Other undisclosed noncurrent assets 13,83513,92315,71415,63016,939588
Total noncurrent assets: 63,29537,03536,63527,93632,76627,590
TOTAL ASSETS: 97,32491,64361,16268,62849,46043,685
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3,9712,3311,3511,4141,1063,316
Taxes payable 26292929 814
Accounts payable 2,040423225216261427
Accrued liabilities 1,9051,8791,0971,1698452,074
Debt 14,334     
Other liabilities 5,3683,8362,3259501,913724
Due to related parties      36
Total current liabilities: 23,6736,1673,6762,3643,0194,076
Noncurrent Liabilities
Liabilities, other than long-term debt 17,93425818437076453
Accounts payable and accrued liabilities  25818437076453
Other liabilities 17,934     
Total noncurrent liabilities: 17,93425818437076453
Total liabilities: 41,6076,4253,8602,7353,0954,529
Equity
Equity, attributable to parent 55,71885,21857,30365,89446,36539,156
Common stock 201916141211
Treasury stock, value (14,993)(13,954)(3,978)   
Additional paid in capital 272,118250,605172,691152,543103,80875,467
Accumulated other comprehensive income (loss) (1,461)(1,469)(390)(1,117)(116)1,568
Accumulated deficit (199,967)(149,982)(111,037)(85,547)(57,338)(37,891)
Total equity: 55,71885,21857,30365,89446,36539,156
TOTAL LIABILITIES AND EQUITY: 97,32491,64361,16268,62849,46043,685

Income Statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 3402242,4146282,505558
Revenue, net3376282,505564
Operating lease, lease income 2,810
Other income 6711,1202,077  
Cost of revenue (62)(136)(162)(745)(2,004)(213)
Cost of goods and services sold   (162)(745)(2,004)(213)
Other undisclosed gross profit   (2,077)(115)124 
Gross profit: 27889175(232)625345
Operating expenses (51,332)(40,730)(27,913)(29,043)(23,354)(13,007)
Other undisclosed operating income 621361628601,880219
Operating loss: (50,992)(40,506)(27,577)(28,415)(20,849)(12,442)
Nonoperating income 1,0091,5652,08921167387
Other nonoperating income 1991,1731,95513263072
Interest and debt expense (482)     
Loss from continuing operations before equity method investments, income taxes: (50,465)(38,941)(25,488)(28,204)(20,176)(12,355)
Other undisclosed income from continuing operations before income taxes 482     
Loss from continuing operations before income taxes: (49,983)(38,941)(25,488)(28,204)(20,176)(12,355)
Income tax expense (benefit) (1)(5)(2)4(729)(51)
Loss from continuing operations: (49,984)(38,945)(25,490)(28,200)(20,905)(12,406)
Loss before gain (loss) on sale of properties:(49,984)(38,945)(25,490)(28,200)(20,905)(15,525)
Loss from discontinued operations      (3,119)
Net loss: (49,984)(38,945)(25,490)(28,200)(20,905)(15,525)
Other undisclosed net income (loss) attributable to parent    (8)1,45751
Net loss available to common stockholders, diluted: (49,984)(38,945)(25,490)(28,208)(19,448)(15,475)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (49,984)(38,945)(25,490)(28,200)(20,905)(15,525)
Other comprehensive income (loss) 8(1,080)967(743)(308)15
Comprehensive loss: (49,976)(40,025)(24,523)(28,943)(21,213)(15,510)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   (240)(265)811,662
Comprehensive loss, net of tax, attributable to parent: (49,976)(40,025)(24,763)(29,209)(21,132)(13,848)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: